The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03).
 
Kazutaka Narui
No Relationships to Disclose
 
Toshinari Yamashita
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Nippon Kayaku; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda
 
Masahiro Kitada
No Relationships to Disclose
 
Hidetoshi Kawaguchi
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
 
Masaya Hattori
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Novartis
 
Tetsuhiro Yoshinami
Honoraria - Chugai Pharma
 
Nobuki Matsunami
No Relationships to Disclose
 
Kazuhiro Yanagihara
No Relationships to Disclose
 
Teru Kawasoe
No Relationships to Disclose
 
Takeshi Nagashima
No Relationships to Disclose
 
Hiroko Bando
No Relationships to Disclose
 
Hiroshi Yano
No Relationships to Disclose
 
Yoshie Hasegawa
No Relationships to Disclose
 
Rikiya Nakamura
No Relationships to Disclose
 
Masahiro Kashiwaba
Speakers' Bureau - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Novartis
Research Funding - Chugai Pharma
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin
Research Funding - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Pfizer
 
Satoshi Morita
Honoraria - Chugai Pharma; Eisai
Research Funding - Eisai
 
Shinji Ohno
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai
 
Masakazu Toi
Research Funding - Chugai Pharma (Inst)